Final CMS rule concludes iovera is a qualifying device for separate payment under the NOPAIN Act ---- Beginning January 1, 2025, providers can ...

The No Pain Act will mandate Medicare insurance coverage for non-opioid pain management, including evidence-based treatments, ...

The former anesthesiologist injected nerve-blocking agent bupivacaine and other drugs into IV bags of saline at Baylor Scott & White Surgicare North Dallas, according to a federal criminal complaint.

Exparel (bupivacaine liposome injectable suspension), to facilitate better insurance coverage for the drug. This new J-code will take effect on Jan. 1, 2025, replacing the existing C-code (C9290 ...

Bupivacaine HCl 2.5mg/mL, 5mg/mL; epinephrine 1:200000; soln for inj. Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical ...

The Food and Drug Administraton has approved Jiangsu Hengrui Pharma's application for bupivacaine liposome, which is a generic of Pacira BioScience's non-opioid pain drug Exparel. Hengrui is the ...

Through his work as a clinical fellow in paediatric surgery at the University Hospital Southampton NHS Foundation Trust, he ...

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

Intradermal testing with lidocaine 1%, mepivacaine 2%, and bupivacaine 0.5% was performed on 8 patients; 3 had positive reactions to lidocaine, and 1 had a positive reaction to mepivacaine.

Operator: Good day, and welcome to the Third Quarter 2024 Pacira Biosciences Inc. Earnings Conference Call. At this time, all ...